Lundquist

TLI Investigator Dr. Wei Yan Named Editor-in-Chief of the Andrology Journal

Retrieved on: 
Monday, March 18, 2024
Reproduction, Lundquist, Managing editor, Infertility, SSR, Male, Social media, Research, Fertility, Doctor of Philosophy, MD, Biology of Reproduction, Society, ELife, Biology, Reproductive medicine, UCLA, Management

Dr. Yan's appointment to Andrology is a testament to his dedication to reproductive medicine.

Key Points: 
  • Dr. Yan's appointment to Andrology is a testament to his dedication to reproductive medicine.
  • With over 160 peer-reviewed publications and numerous awards, Dr. Yan is a committed researcher and educator.
  • Dr. Yan's vision for Andrology is to enhance its global influence and implement innovative strategies.
  • His plans include prioritizing cutting-edge reviews, rewarding high-quality contributions, and fostering the next generation of researchers through the Trainee Reviewer Program.

DUOS Announces Appointment of Three Industry Veterans to its Inaugural Advisory Board

Retrieved on: 
Tuesday, January 30, 2024
Health, Consumer, Technology, Health Technology, Seniors, Health Insurance, Software, Partnership, GuideWell, Causality, CLU, Advisory board, Growth, MD, Lundquist, Golden Rule, MMM, Entrepreneurship, Principle, UnitedHealth Group, Chfc, Learning, Health equity, FAAP, Gavras, Medicare, Management

DUOS, a digital health company empowering older adults to live independently and attain the highest level of health in partnership with health plans, today announced the formation of its inaugural Advisory Board with the appointment of three esteemed healthcare industry executives.

Key Points: 
  • DUOS, a digital health company empowering older adults to live independently and attain the highest level of health in partnership with health plans, today announced the formation of its inaugural Advisory Board with the appointment of three esteemed healthcare industry executives.
  • The introduction of the Advisory Board aligns with DUOS’ commitment to supporting growth initiatives and advancing innovative approaches to delivering solutions that are tailored to the evolving needs of health plans and their valued members.
  • Toth is a highly experienced industry leader in healthcare and financial services, holding CLU and ChFC designations since the 1990s.
  • “As we bring these distinguished leaders into DUOS as part of our newly formed Advisory Board, we all recognize the significant opportunities within our industry,” said Jenn Kerfoot , Chief Strategy & Growth Officer at DUOS.

The Lundquist Institute Receives Gift from the Samberg Foundation to Study the Use of Psilocybin in Alleviating Demoralization and Psychological Distress in Palliative Care

Retrieved on: 
Monday, July 24, 2023
Psilocybin, Lundquist, David Geffen School of Medicine at UCLA, Depression, Face, TLI, Anxiety, Cancer, Quality of life, Death anxiety, Terminal illness, Research, Doctor of Philosophy, Person, Pain, Medicine, CQD, MD, Patient, Grammatical mood, Palliative care, UCLA, FDA, MDMA, Joe, Safety, Pharmaceutical industry, Nursing, New York University

Los Angeles, California, July 24, 2023 (GLOBE NEWSWIRE) -- The Joe & Sandy Samberg Foundation has made a gift of $300,000 to The Lundquist Institute to study the use of psilocybin in alleviating demoralization and the psychological distress associated with life-threatening illness in palliative care.

Key Points: 
  • Los Angeles, California, July 24, 2023 (GLOBE NEWSWIRE) -- The Joe & Sandy Samberg Foundation has made a gift of $300,000 to The Lundquist Institute to study the use of psilocybin in alleviating demoralization and the psychological distress associated with life-threatening illness in palliative care.
  • The gift will facilitate an FDA-approved multi-site clinical trial.
  • Our earlier research with psilocybin suggests that improved mood and lessening of death anxiety and demoralization can occur, even in the context of extreme and dire health circumstances.
  • We are very thankful to the Samberg Foundation for this gift, which allows us to continue to explore this promising therapy in FDA-clinical trials.”

Lundquist Institute Investigator Dr. Matt Budoff Receives $1 Million Gift from the Stanley W. Ekstrom Foundation

Retrieved on: 
Tuesday, November 22, 2022
Acute coronary syndrome, David Geffen School of Medicine at UCLA, Harbor–UCLA Medical Center, Risk, Degenerative disease, Patient, Inflammation, Stanley, Plaque, UCLA, Atheroma, Atherosclerosis, Lundquist, Research, Institute of Health and Biomedical Innovation, Division, Coronary artery disease, CAD, Pharmaceutical industry, Colchicine, Cardiology, Medicine

This gift will directly support the work of Dr. Matt Budoff, a Lundquist Investigator whose research is devoted to advancing procedures that can help doctors identify patients early that are at high-risk for cardiac events and progression of atherosclerosis.

Key Points: 
  • This gift will directly support the work of Dr. Matt Budoff, a Lundquist Investigator whose research is devoted to advancing procedures that can help doctors identify patients early that are at high-risk for cardiac events and progression of atherosclerosis.
  • Our gifts are for very specific purposes, said Steve Silverstein, President of the Stanley W. Ekstrom Foundation.
  • We are very pleased to have made this gift and look forward to the results of his research on Colchicine.
  • I am excited to embark on this study and discover whether this anti-inflammatory medication can make a difference in our patients.

Lundquist Institute Investigator Dr. Eric Daar and Research Team Find That HIV Patients Benefit from Ingestible Sensor Technology on HIV Treatment

Retrieved on: 
Tuesday, November 15, 2022
UCLA School of Dentistry, Population health, LOS, Harvard University, Monitoring, Information technology, David Geffen School of Medicine at UCLA, Harbor–UCLA Medical Center, Mental health, Yale University, ARV, Patient, Edible, Media contacts database, HIV-AIDS, HIV Medicine, UCLA, Lundquist, Research, Management of HIV/AIDS, Record, Institute of Health and Biomedical Innovation, Division, Nebraska Medicine, HIV, National Institute of Mental Health, OIP Sensor Systems, HIV/AIDS, Pharmaceutical industry, Medical device, Dentistry, Medicine

The findings Ingestible Sensor System for Measuring, Monitoring and Enhancing Adherence to Antiretroviral Therapy: An Open-label, Usual Carecontrolled, Randomized Trial were published on November 11 in The Lancet Ebiomedicine.

Key Points: 
  • The findings Ingestible Sensor System for Measuring, Monitoring and Enhancing Adherence to Antiretroviral Therapy: An Open-label, Usual Carecontrolled, Randomized Trial were published on November 11 in The Lancet Ebiomedicine.
  • The team of researchers included investigators from UCLA, Nebraska Medical Center, Yale University, and Harvard University.
  • When ingested, it is sensed by a patchwith an embedded monitor and sensor that isworn by the patient.
  • Our study delivered especially promising results for those who have significant challenges in adhering to antiretroviral medications.

Lundquist Institute Investigator Eiji Yoshihara, PhD., Receives Internationally Prestigious Award for Research on Type 1 Diabetes

Retrieved on: 
Wednesday, March 16, 2022
Media contacts database, Survival, Mortality, Gaps, Quality of life, Lundquist, Therapy, Disease, Risk, COVID-19, Organogenesis, Immune tolerance, Stroke, JDRF, Insulin, Research, Cancer, Diabetes, Holm–Bonferroni method, CEO, Death, Pharmaceutical industry, Public relations

LOS ANGELES, March 16, 2022 /PRNewswire/ -- The Lundquist Institute's investigator Eiji Yoshihara, Ph.D., has received a five-year $749,995.50 Career Development Award from JDRF (formerly known as Juvenile Diabetes Research Foundation) for his proposed study on how human β cells gain immune evasive function by environmental cues. In pre-clinical humanized models, induction of immune-evasive function in stem cell derived functional human islet-like oganoids has proven to cure diabetes by reducing the risk of graft rejection. The goal of Yoshihara's study, "Transcriptional memory in human islet organogenesis", is to understand the molecular basis of human organogenesis with de novo transformation into a more immune tolerance condition.

Key Points: 
  • According to Dr. Yoshihara, "Despite decades of research, significant gaps remain elusive in our understanding of the islet survival in a harsh immune reactive environment.
  • "I congratulate Dr. Yoshihara for receiving this notable award from JDRF," said Dr. David I. Meyer, President and CEO of The Lundquist Institute.
  • There is a projected increase to over 783 million diabetic individuals by the year 2045 according to the International Federation Diabetes Atlas.
  • Specifically, Type 1 diabetes usually appears during adolescence and increases the risk of mortality and reduces the quality of life.

CAPIO'S COMMITMENT TO HOSPITALS AND PATIENTS DRIVES RECORD-BREAKING GROWTH; COMPANY EXPANDS AND STRENGTHENS SALES TEAM

Retrieved on: 
Wednesday, February 16, 2022
Satis (goddess), Indiana State University, Patient, SFC Richard Stayskal Military Medical Accountability Act of 2019, Marketing, Lundquist, Region, Business development, Support, Customs Operational Battle Force Response Assault, Hill, Multimedia, LLC, Organization, Pharmaceutical industry, Management, Operation

Changes to the sales team include:

Key Points: 
  • Changes to the sales team include:
    Capio, one of the largest healthcare asset management companies in the country, is announcing several promotions and new hires to its sales team.
  • "These promotions and new additions to our sales team demonstrate our commitment to providing best-in-class service to our medical provider customers and consumers," said Kutchel.
  • Hill joins Capio as Regional Vice President of West Sales, where she will be responsible for sales operations, client receivables and inventory for the Western United Sates.
  • A seasoned healthcare professional, Nelson takes on the role of Regional Vice President of Sales and Client Engagement for Capio.

Lundquist Institute Investigator Aims to Improve Stroke Recovery with New Granular Biomaterials

Retrieved on: 
Thursday, February 3, 2022
Pennsylvania State University, Media contacts database, Patient, National Institute of Neurological Disorders and Stroke, University, National, Centers for Disease Control and Prevention, Brain, Immunomodulation, Inflammation, Center, BRAIN, Research, Stroke, Lundquist, Lists of diseases, Axon, History of the University of California, Los Angeles, Neurology, National Institutes of Health, Chemical engineering, Doctor of Philosophy, Paralysis, UCLA, Quality of life, Biomedical engineering, National Institute, Pharmaceutical industry

The Centers for Disease Control and Prevention estimate that someone in the United States has a stroke every 40 seconds .

Key Points: 
  • The Centers for Disease Control and Prevention estimate that someone in the United States has a stroke every 40 seconds .
  • According to Dr. Nih, an assistant professor at the University of California Los Angeles (UCLA) and investigator at The Lundquist Institute, if the research project is successful, the use of biomaterials specifically designed to reduce the immune response to stroke while regenerating new vessels in the injured brain, could significantly improve stroke patients recovery and quality of life.
  • Previously, researchers have injected the stroke lesion with a type of engineered biomaterial known as hydrogel materials to aid in tissue repair.
  • However, these biomaterials are not designed specifically to promote angiogenesis and reduce inflammation, limiting how they contribute to stroke recovery.

AMGEN AND BIOLABS LA AT THE LUNDQUIST INSTITUTE ANNOUNCE THAT KARMA BIOTECHNOLOGIES WILL RECEIVE THE SECOND AMGEN GOLDEN TICKET

Retrieved on: 
Monday, January 10, 2022
Karma, Doctor of Philosophy, 100 Best Workplaces in Europe, Patient, Research, TLI, Biotechnology, Biology, Golden Ticket, Partnership, NASDAQ, CEO, Autoimmunity, Autoimmune disease, Disease, Solution, Fortune, Creative Biolabs, Acceleration, Dow Jones Industrial Average, Industry, Program, Allergy, Lundquist, Genetics, Barron's, MD, Therapy, Benaroya Research Institute, AMGN, Degenerative disease, Fine chemical, Film, Pharmaceutical industry, Xavin, Amgen

THOUSAND OAKS, Calif., Jan. 10, 2022 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and BioLabs LA at the Lundquist Institute today announced that Karma Biotechnologies has been awarded the second Amgen Golden Ticket in Southern California.

Key Points: 
  • THOUSAND OAKS, Calif., Jan. 10, 2022 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and BioLabs LA at the Lundquist Institute today announced that Karma Biotechnologies has been awarded the second Amgen Golden Ticket in Southern California.
  • Karma Biotechnologies will receive one year of lab space at BioLabs LA at the Lundquist Institute (TLI) as well as additional facility benefits and connections to Amgen's scientific and business leaders.
  • The Amgen Golden Ticket winner was chosen by an internal team of Amgen scientific leaders at a virtual pitch event.
  • Philip Tagari, vice president of Therapeutic Discovery at Amgen
    "BioLabs LA at the Lundquist Institute is very pleased to participate in another successful Golden Ticket round with Amgen, a true pioneer in biotechnology.

The Lundquist Institute receives prestigious CIRM Scholar Research Training Award

Retrieved on: 
Friday, September 24, 2021
California, California Institute for Regenerative Medicine, Regenerative medicine, Program, CIRM, Student, Institute, Senior, CEO, Public affairs, Lundquist, Research, Doctor of Philosophy, TLI, Pharmaceutical industry, Management

The grant will also make it possible to retain stem cell researchers by providing access to the new and emerging companies based on The Lundquist campus.

Key Points: 
  • The grant will also make it possible to retain stem cell researchers by providing access to the new and emerging companies based on The Lundquist campus.
  • The Lundquist Institute announced that it has received a generous $5 million, 5-year grant from CIRM
    "This is monumental and places the Institute among the ranks of leading research centers for innovative stem cell research" said David Meyer, PhD, President and CEO of the Lundquist Institute.
  • "I want to thank the CIRM as well as all those here at TLI who collaborated to submit our successful application.
  • Coupled with our already in place community outreach programs that are focused on translational research including stem cell research and regenerative medicine, this award will add to the Institute's growing impact as a research powerhouse."